Poster

1001 - IgM Monoclonal Gammopathy Arises Directly from MBL/CLL Cells: Evidence from Proteomic Analyses

1003 - A Phenotypically Distinct Population of CLL Cells with Lower CD20 Expression is Present Within Abdominal Subcutaneous Adipose Tissue of Patients with CLL

1004 - Ubiquitin-like post-translational modifications may modulate the pathogenesis of chronic lymphocytic leukemia mediated by RRAS2

1005 - hnRNPU regulates alternative splicing of Cav1.2 calcium channel: implications in ibrutinib-associated ventricular arrhythmia

1006 - ApoliproteinE induces ferroptosis in chronic lymphocytic leukaemia cells

1007 - Clonality assessment in multiclonal chronic lymphocytic leukemia using Sanger and next-generation sequencing approaches

1008 - Clinical characteristics and outcome of chronic lymphocytic leukemia patients with renal involvement in the era of target drugs

1009 - Epigenetic and transcriptional single-cell profiling reveals CLL-like states in low-count MBL

1010 - Toll-like receptor 9 signalling is a potential tumour escape mechanism following B-cell receptor targeted treatments in subsets of patients with Chronic Lymphocytic Leukaemia.

1011 - A Novel Preclinical Mouse Model of Chronic Lymphocytic Leukemia Driven by BCOR Loss in B Cells

1012 - Evidence For A Pre-Switched Population And Unmutated Immunoglobulin Receptors In IgG-Expressing CLL Stereotyped Subset #4

1013 - The S100A9/EMMPRIN axis is involved in chronic lymphocytic leukemia progression and offers novel therapeutic opportunities

1014 - Highlighting a crucial role for EGR2 mutations in CLL pathogenesis and BTKi resistance

1015 - Monoclonal Gammopathy Defines a Distinct Clinical in Chronic Lymphocytic Leukemia Across Therapeutic Eras

1016 - Integrating phosphoproteomic analysis and innovative 3D cell culture systems to dissect the role of extracellular stiffness in CLL pathogenesis

1017 - Long Non-Coding RNA LINC00173 Regulates BCR Signaling Propensity and mRNA Translation via Ribonucleoprotein Granules in CLL Cells

1018 - Unraveling the NOTCH1/MSI2/c-MYC Signaling Pathway Reveals a Novel Vulnerability in Chronic Lymphocytic Leukemia Progression

1019 - Immunological Landscape of CLL Development and Response to Early BTK Inhibition in del(13q14) Mice

1020 - KRAS^G13D-Dependent PI3K/AKT Signaling Regulates Fatty Acid Oxidation in Chronic Lymphocytic Leukemia

1021 - Normal B Cells in MBL Show Abnormal Transcriptomic and Subset Distributions Compared to Healthy Donors: Evidence for Follicular Maturation in IGHV-Mutated MBL and Extrafollicular Maturation in IGHV-Unmutated MBL

1022 - Unravelling the Clinical and Biological Features of Accelerated Chronic Lymphocytic Leukemia

1101 - An immuno-(epi)genomic classification of chronic lymphocytic leukemia refines outcome prediction

1102 - Unravelling Prognostic Significance: Long-Read Nanopore Sequencing of TP53 and IGHV in Chronic Lymphocytic Leukaemia Patients in Tanzania.

1103 - Identification and multi-omic characterization of a novel molecular subtype of CLL based on EBF1 expression levels

1104 - A Multi-Gene Expression-Based Prognostic Model for Risk Stratification in Chronic Lymphocytic Leukemia (CLL)

1105 - Defining Signalotypes in Chronic Lymphocytic Leukemia and Applying Machine Learning to Better Characterize Biological and Clinical Subgroups

1106 - Genomic characterization of chronic lymphocytic leukemia patients with TP53 alterations from a spanish real-world cohort treated with targeted agents

1107 - Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation

1108 - CLL10000: Robust Classification of 1172 ATM Variants employing a Five-Factor Score derived from matched Non-Tumor Controls

1109 - Integrating clinical and genomic factors to predict time to first treatment in chronic lymphocytic leukemia

1110 - Clinical Profiles of Chronic Lymphocytic Leukemia Patients with SF3B1 Mutations: A Single-Institution Study

1111 - Functional analysis of in-frame variants in TP53 gene identified in adult leukemias: A study of the TP53 Network of European Research Initiative on CLL

1112 - Artificial Intelligence–Driven Clustering of Peripheral Blood Cell Morphology Reveals Disease Heterogeneity and Prognostic Relevance in CLL

1113 - Stereotyped BCR Subset #8 in Chinese CLL: Molecular Genetics, Clinical Behaviour, and Prognosis

1114 - Clonal shifts of TP53 mutations in patients treated with BTK and BCL2 inhibitors: analysis of accompanying genomic changes

1115 - Clonal Evolutionary Dynamics Shaped by Genetic Profiles in Chronic Lymphocytic Leukemia: A New Era in Disease Monitoring and Therapy Resistance

1116 - IGHV Next-Generation Sequencing in CLL: Integrating Mutational Status and Clonotype Tracking for MRD Assessment

1117 - The clinical significance of specific SF3B1 mutation variants in Chinese patients with chronic lymphocytic leukemia

1118 - Optical genome mapping identifies a high number of chromoanagenesis events in chronic lymphocytic leukemia patients with altered TP53

1119 - MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications

1120 - Serum LC-MS based untargeted metabolomics machine learning for distinguishing asymptomatic and symptomatic CLL/SLL and predicting TTFT

1201 - IFNγ/IL21-JAK-STAT1 Signaling Axis Drives T-Cell–Mediated CLL Proliferation and Venetoclax Resistance

1202 - Advanced 3D culture system revealed the dynamic regulation of Podoplanin in CLL cells within the microenvironment

1203 - SF3B1 K700E Mutation Promotes SAT1-Mediated Metabolic Reprogramming and Suppresses T-cell Immune Response in Chronic Lymphocytic Leukemia

1204 - EGR2 Hotspot Mutations Drive BTKi Resistance in Chronic Lymphocytic Leukemia via CD27-CD70 Interaction-Mediated T-Cell Exhaustion

1205 - Investigating the eEF2K/eEF2 axis as a potential target in CLL following nelfinavir treatment

1206 - Subversion of ERK-MAPK-mediated mRNA translation elongation as a therapeutic strategy in CLL

1207 - In vitro investigation of the phenotype of CLL cells during trafficking and homing in a 3D-printed bioreactor

1208 - Selectively targeting foreign antigen to surface membrane IgD leads to enhanced T-cell activation in patients with CLL and normal people

1209 - Early effects of venetoclax monotherapy on immune cells in patients with chronic lymphocytic leukemia

1210 - Imaging mass cytometry reveals distinct cellular architectures in proliferative and non-proliferative regions of the chronic lymphocytic leukaemia lymph node tumour microenvironment

1211 - Unraveling a poor-prognosis CLL subgroup: from IGHV bias and AID activation to altered T-cell profiles

1212 - High-dimensional profiling of CLL and T cell interactions during early phase of disease using a 42-color full-spectrum cytometry panel

1213 - Characterizing the Tumor Microenvironment in CLL: The Role of NK Cells and Prognostic Gene Markers

1214 - CD49d promotes T cell senescence in chronic lymphocytic leukemia

1215 - Expression and signalling patterns of CD180/MD1 and CD150 in Chronic Lymphocytic Leukaemia (CLL) cells and MEC 1 cell line

1216 - BIOLOGICAL FEATURES of B-CLL AND RESIDUAL IMMUNITY AT TREATMENT INITIATION DETERMINE IMMUNITY ON BTKI THERAPY.

1217 - IGHV Repertoire in Israeli CLL Patients Reveals Significant Low Frequency of Stereotyped Subsets – A Single Center Retrospective Study

1218 - CD11c: A Promising Indicator for Zanubrutinib Efficacy Evaluation in High-Risk CLL

1219 - The immunogenicity landscape of CLL and its association with patient outcome

1220 - Chronic Lymphocytic Leukemia and Renal Cell Carcinoma: A Case Series of Twelve Patients

1221 - The Integrin Adaptor Kindlin-3 Regulates Chronic Lymphocytic Leukemia Development and Progression

1223 - Depletion of normal B-cells, defined as < 20 cells/µL by high-sensitivity analysis, identifies early-stage CLL and MBL patients at increased risk of severe infection and early mortality.

1224 - A fraction of lymph node CLL B cells exhibits high expression of T-bet

1225 - Screening People with Persistent Absolute Lymphocytosis Favors the Identification of High-Count Monoclonal B-Cell Lymphocytosis

1226 - Ibrutinib enhances the bias of T-cell responses towards staphylococcal superantigens sustaining inflammation in chronic lymphocytic leukaemia

1227 - Clinical and Biological Impact of Plasma Cytokine Levels in Newly Diagnosed Chronic Lymphocytic Leukemia

1301 - Selective NIK Inhibition Overcomes Microenvironment-Mediated Resistance and Synergizes with Venetoclax in CLL

1302 - Pevonedistat Enhances the Cytotoxic Effect of Rohinitib on B Cells of Chronic Lymphocytic Leukemia

1303 - Targeting Lysosomes in the Chronic Lymphocytic Leukemia Microenvironment

1304 - Linking Cytokine Signaling and Metabolism in Chronic Lymphocytic Leukemia: The Translational Relevance of the IL-12 Family

1305 - CLECL1⁺ Proliferative CLL Cells Remodel the Lymph Node Microenvironment Through Fibroblast Reprogramming, Th2 Polarization, and M2 Macrophage Induction to Promote Immune Evasion and Disease Progression

1306 - Distinctive Features in NF-kB Regulation Favor a Synergistic Action of Pevonedistat and Laduviglusib on B Cells of Chronic Lymphocytic Leukemia

1307 - Developing a novel lipid-based imaging tool for the surveillance of chronic lymphocytic leukemia

1309 - Effects of Pirtobrutinib, a non-covalent BTK inhibitor, on T-cell function in chronic lymphocytic leukemia (CLL)

1310 - Evaluation of two novel Cyclin Dependent Kinase 9 inhibitors for the treatment of Myeloid Cell Leukaemia 1 (MCL1) high Chronic Lymphocytic Leukaemia

1401 - Risk of Second Primary Malignancies in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving First-line Therapy: A Real-World Study

1402 - Cytogenetic instability and therapeutic pressure in Fixed vs Continuous regimens for Chronic Lymphocytic Leukemia after first line treatment: Preliminary Data from an Italian Multicenter Experience

1403 - Factors Influencing the Regimen choice for firSt-line Therapy in Chronic Lymphocytic Leukemia: the FIRST-CLL study

1404 - A Phase 2 study with Tafasitamab and Zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – TaZa CLL Study

1406 - Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult Leukemia Group

1407 - The impact of body mass index on overall survival in chronic lymphocytic leukemia

1408 - Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen

1409 - Factors influencing physician’s choice of fixed-duration ibrutinib+venetoclax or continuous ibrutinib monotherapy in the treatment of patients with previously untreated CLL: physician questionnaire results from the prospective phase 2 TAILOR study

1410 - Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia

1411 - Outcomes, inequities, and access to front-line preferred therapies for chronic lymphocytic leukemia in the United States: a real-world evidence study

1412 - Real-world Utilization of Novel Therapies and Overall Survival among U.S. Medicare Beneficiaries Initiating Frontline Chronic Lymphocytic Leukemia Treatment

1413 - A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 ICLL-07 FILO trial

1414 - Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia /small lymphocytic lymphoma in the phase 2 CAPTIVATE study

1415 - Health-related quality of life in patients with previously untreated chronic lymphocytic leukaemia treated with ibrutinib and rituximab or fludarabine, cyclophosphamide and rituximab: patient-reported outcomes from the multicentre, open-label, randomised, phase 3 FLAIR trial

1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL

1417 - Acalabrutinib Monotherapy versus Acalabrutinib plus Obinutuzumab Combination Therapy in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A ‘Real-World’ Study of Efficacy and Safety

1418 - A Refined Continuous Individualized Risk Index (CIRI2-CLL) for Accurately Predicting Outcomes after Limited-Duration CLL Therapy

1419 - SEQUOIA 5-year Follow-up in Arm C: Frontline Zanubrutinib Monotherapy in Patients with del(17p) and Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

1420 - Combination of Zanubrutinib + Venetoclax for Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results in SEQUOIA Arm D

1421 - Safety and Efficacy of Zanubrutinib in a Subgroup of Older Patients (≥75 Years) With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the SEQUOIA Study

1422 - Risk of Acute Kidney Injury and Cytopenias During Treatment of Chronic Lymphocytic Leukemia in a Nationwide Real-World Cohort

1423 - MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

1424 - Safety Analysis of Fixed-Duration Acalabrutinib-Venetoclax Combinations vs Chemoimmunotherapy: A Post Hoc Analysis From the Phase 3 AMPLIFY Trial

1425 - IGLV3-21R110 as a prognostic marker for early stage CLL patients – clinical implications in patients treated with BTK inhibitors and diagnostic challenges

1426 - Efficacy and Safety of Zanubrutinib in a Fit Subgroup of Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Post Hoc Analyses from the SEQUOIA Study

1427 - A Prospective Multicenter Study of FCR Alternating with Ibrutinib in Treatment-naive Patients with chronic lymphocytic leukemia (CLL)

1428 - A Prospective, Single-Center, Single-Arm Clinical Trial of Zanubrutinib Monotherapy and ZFCG combined therapy was given sequentially for the Treatment of Primary Symptomatic CLL/SLL (Stop Trial)

1429 - Orelabrutinib, fludarabine, cyclophosphamide and obinutuzumab (OFCG) for first-line treatment of chronic lymphocytic leukemia: a multicenter, investigator-initiated phase II trial (cwcll-001 trial)

1430 - Assessing measurable residual disease (MRD) by cell-free DNA (cfDNA): results from a real-world series

1431 - The role of Minimal Residual Disease in chronic lymphocytic leukemia

1432 - Title: A phase Ib study evaluating the safety and efficacy of tafasitamab, acalabrutinib, and obinutuzumab (TAO) in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma

1433 - Ibrutinib plus venetoclax with measurable residual disease-guided duration of treatment is superior to both ibrutinib monotherapy and fludarabine-cyclophosphamide-rituximab for previously untreated chronic lymphocytic leukaemia: Report of the Phase III UK NCRI FLAIR study.

1434 - STATIC TRIAL (Stopping Therapy to Avoid Treatment-resistance In CLL): A randomised phase III trial comparing intermittent with continuous treatment strategies in CLL

1435 - Absence of lymphocytosis after starting treatment with cBTKi is a rare phenomenon except for trisomy 12 and CD49d positive CLL

1436 - Real-World Treatment Utilization Patterns, Discontinuation and Healthcare Resource Utilization of First-Line (1L) Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy in Chronic Lymphocytic Leukemia (CLL): Age-Related Disparity

1437 - Effect of targeted treatment on IGHV subset #2 and #8 patients in CLL: Comparison of MRD defined Ibrutinib plus Venetoclax treatment to the Ibrutinib and FCR arms of the FLAIR Trial

1438 - Central Nervous System Involvement in Chronic Lymphocytic Leukemia: An International Retrospective Study by ERIC, the European Research Initiative on CLL

1439 - Ten-year follow-up of a phase II study of ibrutinib in relapsed/ refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)

1440 - Transcriptional reprogramming and survival co-dependencies of chronic lymphocytic leukemia resistant to venetoclax

1441 - A functional prognostic model predicts progression free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax

1501 - EFFICACY AND TOLERABILITY OF VENETOCLAX PLUS RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA – REAL-WORLD ANALYSIS OF POLISH ADULT LEUKEMIA STUDY GROUP

1502 - Sequencing single novel agent-based therapy for patients with CLL: A retrospective study of patients treated with covalent Bruton Tyrosine Kinase inhibitor (cBTKi) followed by B-cell lymphoma 2 inhibitor (BCL2i) versus BCL2i followed by cBTKi

1503 - Analysis of resistance-related mutations in patients with Chronic Lymphocytic Leukemia treated with BTK or BCL2 inhibitors suggests different underlying resistance mechanisms and subclonal dynamics

1504 - What measure of treatment effect should be preferred ? A critical review of 20 randomized clinical trials of targeted therapies in chronic lymphocytic leukemia

1505 - A Meta-Analysis Investigating Response Rates of Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B-Cell Lymphomas

1506 - Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory CLL: updated findings from an ongoing Phase 1a study

1507 - Allogeneic stem cell transplantation is effective after pathway inhibitor treatments in CLL – a retrospective study on behalf of the Chronic Malignancies Working Party of EBMT

1508 - Measurable Residual Disease in Chronic Lymphocytic Leukemia (CLL) in Clinical Practice: A Single-Center Report Over the Years 2018–2024

1509 - Nemtabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Cohort J of the Phase 2 BELLWAVE-003 Study

1510 - BELLWAVE-010: An Open-Label, Phase 3 Study of Nemtabrutinib Plus Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

1511 - Nemtabrutinib in Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Phase 3 BELLWAVE-011 Study

1512 - Pirtobrutinib after a Covalent BTK Inhibitor in Pretreated Chronic Lymphocytic Leukemia: A Phase 2 Dose Optimization Trial in Progress

1513 - Comparative Assessment of MRD Detection and Immunological Effects in Relapsed CLL Patients Treated with Rituximab-Venetoclax in real world: Insights from the "Dedalus" Protocol

1514 - Updated Results From the Phase 1 Study of Sonrotoclax (BGB-11417), a Novel B-Cell Lymphoma 2 Inhibitor, in Combination With Zanubrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Demonstrate Deep and Durable Responses

1515 - Re-Treatment with Venetoclax-Obinutuzumab after time-limited, MRD-guided Venetoclax-Obinutuzumab: final analysis of 7 patients with chronic lymphatic leukemia (CLL) treated in the CLL2-BAG trial of the GCLLSG.

1516 - Real-World Outcomes of Idelalisib in Relapsed/Refractory CLL Including High-Risk Patients and Post-BTKi/BCL2 Therapy: A Single-Center Experience from 2016 to 2025

1517 - Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis

1518 - Ultrasound assessment of chronic lymphocytic patients during BTK treatment: comparison of dimensional response vs overall ultrasound assessment in general practice. Preliminary results of a prospective study

1519 - Clinical and pharmacoeconomic impact of ultrasound assessment of patients with chronic lymphocytic leukemia treated with BTK inhibitors (BTKi)

1520 - Unveiling the journey of Chronic Lymphocytic Leukemia patients in Portugal: insights into the Rituximab-Venetoclax protocol

1521 - Real-world efficacy and safety of venetoclax +/- rituximab in >75-years old patients or with cardiovascular comorbidities and R/R chronic lymphocytic leukemia: interim results of the VERONE study

1522 - MAVRiC: A Phase 2 Study of Mutation-Guided Finite-Duration Acalabrutinib Plus Venetoclax for Relapse After Frontline Finite-Duration Covalent Bruton Tyrosine Kinase Inhibitor Plus Venetoclax‒Based Combination Therapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

1523 - SOUNDTRACK-E: A Phase 1/2 Open-label Multicenter Study to Evaluate the Safety/Efficacy of AZD0486 as Monotherapy or in Combination With Acalabrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

1524 - Patient-Reported Outcomes (PRO) among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) receiving Pirtobrutinib: Final Analysis from the BRUIN Phase 1/2 Study

1525 - Updated Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Ongoing Phase 1 CaDAnCe-101 Study

1526 - Ibrutinib and acalabrutinib in the treatment of relapsed/refractory chronic lymphocytic leukemia: a real-world analysis from the Czech Chronic Lymphocytic Leukemia Patients Registry

1527 - Ibrutinib can be effective even at the lowest dose after 10 years of treatment

1528 - Estimating the Cardiac Deaths Associated with Treating Chronic Lymphocytic Leukemia with Ibrutinib versus Zanubrutinib in the United States

1529 - Prevalence of BTK, PLCG2, and BCL2 mutations in CLL patients in Croatia - KROHEM study

1601 - Central Nervous System Involvement in Patients with Richter Transformation

1602 - Venetoclax in combination with chemotherapy in Richter Syndrome patients: a real-life experience

1603 - Single-cell transcriptome analysis reveals molecular mechanism of stem-like cells in Richter Transformation

1604 - The CDK2/9 inhibitor fadraciclib in Richter transformation

1605 - Phase 2 study of the combination of lisocabtagene maraleucel, nivolumab, and ibrutinib in Richter’s transformation - NCT05672173

1701 - Development and evaluation of a selection-algorithm optimised ensemble model for predicting infection risk in CLL using structured and unstructured electronic patient record data

1702 - Immune Cytopenia with Chronic Lymphocytic Leukemia: A Real-World Clinical Characteristic Analysis

1703 - Targeting immunoglobulin deficiency in CLL: A retrospective evaluation of IgM/IgA-enriched IVIg use in a small cohort of patients from Argentina

1704 - Feasibility of an individualized physical activity Intervention in CLL patients receiving ibrutinib +/-venetoclax: preliminary results from the QOLIBRI Study

1705 - Inequalities in the diagnosis and survival of 30,071 people consecutively diagnosed with chronic lymphocytic leukaemia in England between 2014 and 2021: preliminary analysis from the UNCOVER Study Group

1706 - A Qualitative Study to Explore the Patient Experience of Continuous Covalent Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Study Methodology

1707 - Evaluating CLL/SLL Clinical Trials: A Participation-to-Prevalence Analysis Using Institutional and SEER Data from 2012-2024

1708 - Chronic Obstructive Pulmonary Disease and Previous Pneumonia have an impact on infectious complications in patients with Chronic Lymphocytic Leukemia treated with Acalabrutinib and Zanubrutinib: a Multicentre SEIFEM Study.

1709 - Impact of Dose Intensity of Ibrutinib on Clinical Outcomes of CLL Patients: Analysis of the EVIdeNCE Study

1710 - A nomogram for survival prediction based on socioeconomic factors in patients with chronic lymphocytic leukemia: an analysis of SEER database

1711 - A 3 week pause versus continued BTKi during vaccination (IMPROVE): a randomised, open-label, superiority trial.

1712 - Other Cancers in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

1713 - An assessment of NK and T cell functional immunity in response to vaccination whilst taking acalabrutinib or ibrutinib monotherapy.

1714 - Trends and Predictors of Engagement in Preventive Health Measures in Patients with Chronic Lymphocytic Leukemia: A Prospective Analysis of Vaccinations and Cancer Screening Practices

1715 - Real-World Outcomes Following Pemivibart (Pemgarda™) for COVID-19 Prophylaxis in Immunocompromised Patients with Hematologic Malignancies

1716 - Incidence of second primary malignancies in Chronic lymphocytic leukemia

1717 - MVA-based GEO-CM04S1 vaccine results in improved cellular immune response in patients with chronic lymphocytic leukemia (CLL) compared with mRNA-based vaccine: initial results of a Phase II randomized study

1801 - Targeting BTKi-Resistant CLL Using the Dual Irreversible/Reversible 4th Generation BTK Inhibitor Rocbrutinib

1802 - Targeting SF3B1 Disrupts Chronic Lymphocytic Leukemia Survival via PFKFB-mediated Glycolytic Dependency

1803 - Real-world Treatment Outcomes among Patients with High-Risk CLL/SLL Receiving Venetoclax-Based Therapy in 1L or 2L: An Updated International Study

1804 - BRD4 maintains the surface phenotype of Chronic Lymphocytic Leukemia cells

1805 - Targeting the p53/xCT/GSH axis with PRIMA-1Met combined with Sulfasalazine shows therapeutic potential in Chronic Lymphocytic Leukemia

1806 - Dual mTORC1/2 Inhibition by Torin 2 Induces Cytotoxic and Cytostatic Effects in In Vitro Models of Chronic Lymphocytic Leukaemia

1807 - Therapeutical potential of NRF2 inhibition by Brusatol in Chronic lymphocytic leukemia and in combination with current therapy

1808 - Setting a 3D model to study Chronic Lymphocytic Leukemia

1901 - Similarities and Differences in Immune Modulation by Acalabrutinib and Zanubrutinib in Chronic Lymphocytic Leukemia

1902 - Impact of treatment with ibrutinib or venetoclax on CAR-T cell generation in patients with chronic lymphocytic leukemia. Interim analysis of the GIMEMA CLL2020 study

1903 - Hematopoietic Progenitor Kinase-1 (HPK-1) Inhibition Improves the In Vitro Efficacy of
Bispecific Antibodies in CLL

1904 - Development and implementation of a novel flow cytometry CD19-agnostic MRD assay in CLL, including in patients treated with anti-CD19 antibody tafasitamab

1905 - Academic CD19-directed CAR-T ARI-0001 (varnimcabtagene autoleucel) for patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation

1906 - Fibroblast mediated Modulation of bispecific Antibody Treatment in Chronic Lymphocytic Leukemia

1907 - Autoimmune cytopenias in patients with chronic lymphocytic leukemia receiving acalabrutinib treatment.

1908 - Number Needed to Treat Analyses of Zanubrutinib vs Acalabrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia

1909 - A Network Meta-Analysis (NMA) of Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax in Treatment-naïve (TN) Chronic Lymphocytic Leukemia (CLL)

1910 - Comparative Efficacy of Zanubrutinib (ZANU) versus Fixed-Duration Acalabrutinib Plus Venetoclax (AV) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC)

1911 - Prospective Patient Preference Study for Chronic Lymphocytic Leukemia (CLL) Treatment Attributes Impacting Patient Shared-Decision Making

2001 - Comparative Analysis of Patients’ Characteristics, Treatment, and Survival Outcomes in CLL from China and the US

2002 - Improving information provision to enhance chronic lymphocytic leukaemia (CLL) care in resource-limited countries

2003 - Evaluating Gaps and Opportunities in Chronic Lymphocytic Leukemia Treatment Access: Institutional Capacity Assessments in 18 LMICs

2005 - Expression of TP53 deletion and Clinical Presentations of Nigerians with Chronic Lymphocytic Leukaemia: A Preliminary Report

2006 - Understanding the unmet needs in diagnostics and therapeutics of chronic lymphocytic leukemia in Korea

LB01 - A Rare Case of t(8;16)(p11.2;p13.3) and del(17p) That Shows Both Acute Myeloid Leukaemia and Chronic Lymphocytic Leukaemia at the Same Time

LB02 - Efficacy of Fludarabine-based Regimen in the Treatment of Chronic Lymphocytic Leukaemia: A 10-year Comparative Analysis from a Resource-Limited Setting

LB03 - Exploration of Early Signalling Events of CLL upon Exposure to Low Dose Combination of Ibrutinib and Venetoclax

LB04 - Factors predicting pulmonary infections in chronic lymphocytic leukemia (CLL) treated with targeted therapies with a history of lung diseases: factors are IGHV, TP53 (low and high burden) and COBBLL1

LB05 - Integrated immunogenetic and cytogenetic profiling reveals distinct biological patterns among stereotyped BCR subsets in CLL

LB06 - Investigating 17p-Deletion in Chronic Lymphocytic Leukaemia: A Study of Tumour-Suppressive microRNAs

LB07 - Risk Stratification in Chronic Lymphocytic Leukemia by IgHV Status and Mutational Co-Occurrence Profiling

LB08 - Secondary factors in chronic lymphocytic leukemia (CLL) such as COBBLL1 and response prediction in TP53 non-mutant cohort treated with single agent venetoclax or Obinutuzumab

LB09 - XPO1 Inhibitor Selinexor Induces Heme Oxygenase-1 Mediated p53-Dependent Mitochondrial Ferroptosis in Chronic Lymphocytic Leukemia